Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

UNITED THERAPEUTICS (UTHR) Research & Development: 2009-2025

Historic Research & Development for UNITED THERAPEUTICS (UTHR) over the last 17 years, with Sep 2025 value amounting to $127.5 million.

  • UNITED THERAPEUTICS's Research & Development rose 23.19% to $127.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $544.3 million, marking a year-over-year increase of 9.17%. This contributed to the annual value of $481.0 million for FY2024, which is 17.89% up from last year.
  • As of Q3 2025, UNITED THERAPEUTICS's Research & Development stood at $127.5 million, which was down 4.85% from $134.0 million recorded in Q2 2025.
  • In the past 5 years, UNITED THERAPEUTICS's Research & Development ranged from a high of $303.7 million in Q1 2021 and a low of $66.1 million during Q3 2022.
  • Its 3-year average for Research & Development is $118.1 million, with a median of $127.5 million in 2025.
  • As far as peak fluctuations go, UNITED THERAPEUTICS's Research & Development surged by 314.89% in 2021, and later tumbled by 77.28% in 2022.
  • UNITED THERAPEUTICS's Research & Development (Quarterly) stood at $82.9 million in 2021, then rose by 13.27% to $93.9 million in 2022, then surged by 61.24% to $151.4 million in 2023, then dropped by 11.62% to $133.8 million in 2024, then rose by 23.19% to $127.5 million in 2025.
  • Its last three reported values are $127.5 million in Q3 2025, $134.0 million for Q2 2025, and $149.0 million during Q1 2025.